OmNarayanPandeyMD

Oncology • Austin, TX

Assistant Professor, Internal Medicine, University of Texas Southwestern Medical Center, Southwestern Medical School

Join to view full profile

Are you Dr. Pandey?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 50 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
313 E 12th St
Austin, TX 78701
Phone+1 512-324-9650

Fax+1 512-324-8962

Summary

Dr. Om Pandey, MD is an oncologist in Austin, Texas. He is currently licensed to practice medicine in Texas, Minnesota, and Iowa. He is affiliated with University Medical Center at Brackenridge, Dell Seton Medical Center at The University of Texas, and Ascension Seton Medical Center Austin.

Education & Training

University of MinnesotaFellowship, Hematology and Medical Oncology, 2006 - 2008
Howard UniversityFellowship, Medical Oncology, 1998 - 1999
New York-Presbyterian/QueensResidency, Internal Medicine, 1995 - 1998
G.S.V.M Medical College KanpurClass of 1986

Certifications & Licensure

TX State Medical License 2008 - 2026
MN State Medical License 2005 - 2025
IA State Medical License 1999 - 2007
KY State Medical License 1998 - 1999
MI State Medical License 1998 - 1999
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery Start of enrollment: 2010 Mar 01
Terminated
Phase 3
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. Start of enrollment: 2015 Jun 09
Completed
Phase 3
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

2 citations
Chronic lymphocytic leukemia and apparent hyperkalemia.
Aneesh George, Om Pandey, Alejandro Moreno
Cleveland Clinic Journal of Medicine. 2012-10-01
Recurrent giant back proliferating pilomatricoma leading to significant patient morbidity - a case report.
Mihailo Miljanic, Ye Aung, Rajvi Patel, Katrina Samson, Christian Shannon
International Journal of Dermatology. 2021-08-04

Press Mentions

Breast Cancer Is the Leading Cancer Death Among Black Women, a New Study FoundOctober 27th, 2022